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Objective: One of the most common forms of bladder dysfunction is related to the development of
unstable bladder contractions (bladder overactivity). Solifenacin is a relatively new, selective, anti-
muscarinic agent that has been shown to be particularly useful in the treatment of overactive bladder
(OAB) dysfunctions in both men and women. Experimentally, we have demonstrated that OAB and
obstructive bladder dysfunction are associated with the generation of free radicals and oxidative damage
to the bladder. The hypothesis tested was that solifenacin þ coenzyme Q10 þ a-lipoic acid (CoQ þ LA)
would be more effective in the treatment of OAB than either would be individually.
Materials and methods: Forty-eight male White New Zealand rabbits were separated into 8 groups of 6
rabbits each. The following oral treatments were given to each group: Groups 1 and 5, vehicle (saline);
Groups 2 and 6, solifenacin; Groups 3 and 7, CoQ þ LA; Groups 4 and 8, solifenacin þ CoQ þ LA. After
three weeks of treatment (by oral gavage), the rabbits in Groups 1e4 received partial outlet obstruction
as detailed above. The rabbits continued their treatments for four weeks following surgery. At the end of
this four-week period, immediately following urodynamic and physiological studies, the bladder was
excised and the muscle and mucosa were separated and frozen for biochemical research.
Results: The following marker enzymes were quantitated: choline acetyltransferase, citrate synthase,
catalase, superoxide dismutase, and malondialdehyde (MDA, marker for lipid peroxidation). Solifenacin
had no effect on citrate synthase activity of the bladder smooth muscle. However, pretreatment with
both the antioxidants or the combination of solifenacin þ antioxidants protected the citrate synthase
activity such that it remained at control values. Partial outlet obstruction (PBOO) resulted in a 60%
decrease in choline acetyltransferase activity (ChAT) activity, while solifenacin had no effect on reduced
ChAT activity. Both the antioxidant and combination therapy resulted in maintaining ChAT activity at
control values. PBOO resulted in a signiﬁcant increase in MDA of both the muscle and mucosa. For both
tissues, all treatments resulted in a signiﬁcantly lower MDA content. In general, the results demonstrate
the combination of solifenacin þ antioxidants was more effective than either solifenacin or antioxidants
alone.
Conclusion: The addition of the antioxidants CoQ þ LA works synergistically with solifenacin in the
treatment of obstructive bladder dysfunction and OAB.
Copyright  2011, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.ny College of Pharmacy and
12208, USA. Tel.: þ1 518 694
n).
ciation. Published by Elsevier Taiw1. Introduction
The urinary bladder is a smooth muscle organ whose function
is to collect and store urine at low intravesical pressures and then
to periodically expel urine via a highly coordinated, sustained con-
traction.1e3 One of the most common forms of dysfunction is related
to the development of overactive bladder dysfunction (OAB).4,5 Inan LLC. Open access under CC BY-NC-ND license.
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plasia (BPH) and results in the symptoms of urgency and frequency.
In females, unstable bladder contractions can result in urgency and
frequency and can also induce urge incontinence. The incidence of
incontinence increases signiﬁcantly with age and is especially
prevalent after menopause.5,6
Most forms of overactivity/unstable bladder contractions are
mediated through the the release of acetylcholine and stimulation
of muscarinic receptors localized on the detrusor smooth muscle
membranes.7,8 Treatment for overactivity has traditionally used
anti-muscarinic agents.
Solifenacin is a relatively new, selective, anti-muscarinic agent
(M-3) that has been shown to be particularly useful in the treatment
of OAB dysfunctions in both men andwomen.9e13 However, it is not
clear whether there is a selectivity for the muscarinic mechanisms
involved in OAB activity comparedwith themuscarinicmechanisms
involved in micturition. Additionally, it is clear that BPH-induced
bladder hypertrophy can alter the muscarinic receptor subtype
distribution in the bladder and thus modify solifenacin’s
activity.14e16 The etiology of bladder dysfunction secondary to
BPH (OAB and poor bladder contraction) is, in part, caused by the
generation of free radicals and oxidative damage to the bladder
smooth muscle and nerves.17,18
The combination of coenzyme Q10 (CoQ10) and alpha lipoic acid
(LA) have proven to be very potent at preventing oxidative damage
to thebladder causedbybothdirect ischemia/reperfusionandpartial
outlet obstruction.19e21 This combination of supplements signiﬁ-
cantly protected against the contractile, biochemical, and structural
dysfunctions associated with increased free radical production.
The current study was designed to evaluate the hypothesis
that solifenacin can work in synergy with CoQ10 and LA. Part one
of this two-part study demonstrated that the combination of
solifenacin þ CoQ10 and LA were signiﬁcantly more effective than
either treatment alone in improving urodynamics, compliance, and
in situ and in vitro contractile responses to a variety of contractile
agonists. This current study presents the results of our biochemical
tests.
2. Methods
All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Stratton V Medical
Center, Albany, NY, USA.
2.1. Partial outlet obstruction22e24
Each rabbit was anesthetized, the bladder catheterized per
urethra and then exposed through a midline incision. A 00 silk
ligature was snugly tied around the catheterized proximal urethra
and the catheter removed. This has been shown to be an excellent
model of BPH-induced obstructive bladder dysfunction in men.25,26
Approximately 50% of these rabbits developed OAB, as observed
during cystometry. Those rabbits that showed OAB progressed to
severe bladder dysfunction at a signiﬁcantly faster rate than rabbits
that did not show OAB; this is similar to what happens with men
with BPH and OAB. The etiology for obstructive bladder dysfunction
has been shown to be via ischemia and free radical generation and
damage.
2.2. In situ OAB27e29
Each rabbit was anesthetized and the right external carotid
artery cannulated for blood-pressure monitoring. A polyethylene
catheter was inserted through the rabbit’s right femoral artery until
it reached the lower abdominal aorta. A heparinized, saline-ﬁlledpolyethylene catheter was used for intra-arterial administration
of acetylcholine (Ach). The bladder was exposed through a midline
incision of the abdominal wall, and catheterized through the
bladder dome for both monitoring bladder pressure and infusion of
saline. At this point, a ligature was placed around the external
proximal penis and the bladder ﬁlled to 30 ml. Ach was given intra-
arterially and the maximal pressure generated was recorded.
Within 30 minutes, the majority of rabbits developed overactivity,
and the amplitude and frequency of the overactivity were recorded.
Forty-eight male White New Zealand rabbits were separated
into eight groups of six rabbits each. The following oral treatments
were given to each group:
Groups 1 and 5: vehicle (saline)
Groups 2 and 6: solifenacin (0.3 mg/kg/day)
Groups 3 and 7: alpha lipoic acid (100 mM/kg/day) þ coenzyme
Q10 (5 mg/kg/day)
Groups 4 and 8: solifenacin (0.3 mg/kg/day) þ alpha lipoic acid
(100 mM/kg/day) þ coenzyme Q10 (5 mg/kg/day).
After three weeks of treatment (by oral gavage), the rabbits
in groups 1e4 were anesthetized with isoﬂuorane (1e3%) and
received partial outlet obstruction, as detailed above. The rabbits
continued their treatments for four weeks post-surgery.
At the end of this four-week period, cystometry was performed
on each rabbit and they then underwent the in situ study for OAB,
as described above.
Immediately following the in situ experiment, the bladder was
excised, weighed, and three full-thickness bladder strips were
taken for in vitro contractile studies. The balance of the bladder was
separated by blunt dissection into muscle and mucosal compart-
ments, frozen under liquid nitrogen, and stored at -80C for
biochemical experiments. Part 1 reports on the urodynamic and
physiological results of this study, while part 2 reports on the
biochemical aspects.
2.3. Biochemical analyses
2.3.1. Citrate synthase, biomarker for mitochondrial function
Frozen tissue samples of muscle andmucosawere homogenized
at 55.6 mg/ml in ice-cold Tris buffer (50 mM, pH 7.6) and centri-
fuged at 800  g for 10 minutes to remove the cell membranes
and nuclei. A sample aliquot (40 ml) of supernatant was added to
a 0.5 cm cuvette along with 1.1 ml 0.05 M Tris buffer (pH 7.6), 30 ml
12.3 mM acetyl-coenzyme A (acetyl-CoA), 100 ml 1 mM 5,5’-
dithiobis -2 -nitrobenzoic acid (DTNB), and 40 ml 10% Triton X-100.
The reaction was started by adding 50 ml 10 mM oxaloacetate
(substrate). The free coenzyme A generated by citrate synthase
activity reacts with DTNB to form a colored compound that is
quantiﬁed at 412 nm. Absorbance was recorded every 2 minutes for
16 minutes (reaching steady state) using a Hitachi spectropho-
tometer (Hitachi Co. Chicago, Ill). Citrate synthase activity is given
as nanomoles of coenzyme A generated per minute per mg protein.
2.3.2. Choline acetyltransferasedbiomarker for cholinergic
synapses
Frozenmuscle tissue samples were homogenized at 50mg/ml in
a 20 mM EDTA buffer pH 7.6 and centrifuged at 20,000  g for 30
minutes to remove the cell membranes, mitochondria, and nuclei.
One hundred milliliter aliquots were incubated at 37C for 30
minutes with 100 m1 of reaction mixture consisting of 0.04 mM
acetyl-CoA (substrate), 0.50 mCi 3H-acetyl-CoA (200 mCi/mmol),
8 mM choline, 50 mM sodium phosphate, 300 mM sodium chloride
and 96 nM physostigmine. After incubation, each solution was
diluted with 1 m1 of 0.01 M sodium phosphate and the reaction
Table 1
Values for citrate synthase activity, choline acetyltransferase activity, and malon-
dialdehyde (MDA) content for control (untreated) animals. No treatments had any
signiﬁcant effect on these values. Each value is the mean  SEM of six individual
rabbits.
Parameter Muscle Mucosa
Citrate synthase (nM coenzyme A/min/mg protein) 12.0  2.1 66.6  6.7*
Choline acetyltransferase (fmol Ach/mg protein) 3.55  0.9
MDA (mmol/mg protein) 0.56  0.11 1.06  0.2*
* ¼ signiﬁcantly different from muscle; p < 0.05.
Ach ¼ acetylcholine.
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nylboron. Then, the contents of each reaction tubewere transferred
to a 7-ml scintillation vial and 3 ml of Insta-Fluor Plus scintillation
ﬂuid were slowly added to each vial and the vials shaken lightly.
Samples were stood for 1 hour while the phases separated,
extracting 3H-Ach into the Insta-Fluor phase, while 3H-acetyl-CoA
stayed in the aqueous phase. The aqueous phase was removed and
3H-ACh measured using scintillation spectroscopy. Choline acetyl-
transferase activity (ChAT) activity was reported as fmoles acetyl-
CoA generated per minute per mg protein.
2.3.3. Malondialdehydedmarker for lipid peroxidation
Frozen samples of bladder muscle and mucosa were weighed
and thawed in 1.15% KCl-0.05 M Tris buffer, pH 7.4 on ice and
homogenized at 20 mg/ml with a Polytron homogenizer (Brinkman
Co, Westbury, NY). Homogenates were spun at 800  g for 10
minutes and supernatants saved. The reaction system was as
follows: 1.15% KCl-0.05 M Tris, 1 mM and 500 ml tissue extract.
Samples were incubated at 37C for 30, 60, and 120 minutes. At the
end of incubation, the reaction was stopped by adding 100 ml of
sample to microtubes containing 30 ml of 40% trichloroacetic acid.
Tubes were centrifuged at 1000  g for 2 minutes. After centrifu-
gation,100 ul of supernatantwas incubatedwith 750 ml of perchloric
(PCA)/thiobarbituric acid (TBA) solution (2.3% PCA, 0.53% TBA, pH
7.4) at 90C for 30 minutes in 1075 mm test tubes. After this time,
the samples were placed on ice for 10 minutes to cool. To each tube,
2 ml of 1-butanol was added and they were then vortexed for 5e10
seconds. Tubes were spun at 1000  g for 5 minutes and the basal
malondialdehyde (MDA) content of the upper layer was measured
ﬂuorometrically at 532 nm.
Quantitation of total protein was performed using Micro BCA
Protein Assay (Pierce, Rockford, IL, USA) and results are expressed
as nmol MDA/mg protein.
2.3.4. Catalase and superoxide dismutasedendogenous antioxidant
enzymes
Superoxide simutase (SOD) (total) activity was determined by
the standard biochemical methods30e32 using a cytochrome C
reduction test. In thismethod, oxygen free radicals are generated by
xanthine oxidase reactions with ferricytochrome C. SOD activity is
calculated via the degree of inhibition of this reaction and recorded
as the change in optical density (mOD) at 550 nm (using a Hitachi
spectrophotometer) per milligram of protein.
Speciﬁcally, bladder tissue was homogenized in a 50 mM phos-
phate buffer, pH 7.8, at a concentration of 200 mg/ml. The homog-
enate was centrifuged at 2500 rpm for 10 minutes. The pellet was
eliminated and the supernatant was used for the following assay:
1 ml of solution A (0.76 mg xanthine in 10 ml 0.001 NaOH added to
50 mg cytochrome C þ 3.7 mg EDTA in 100 ml 50 mM phosphate
buffer at room temperature) was incubated with 25 ml of the tissue
sample or Cu-Zn SOD standards in a 3-ml cuvette. One hundred
microliters of solution B (5.63 ml xanthine oxidase in 1 ml 0.1 mM
EDTA) was used to start the reaction. After mixing, the absorbance
change indicating cytochrome C reduction was measured in a spec-
trophotometer at 550 nm for 2 minutes. The change in absorbance
with time over the ﬁrst two minutes for all preparations was linear.
Quantitative comparisons were made by the concentration of
enzyme (protein) that inhibited the reaction by 25% (IC25).
Although the IC50 is used more widely, several of the preparations
did not reach 50% inhibition.
Puriﬁed Cu-Zn SOD (purchased from Sigma Chemical Co., St
Louis, MO, USA) was prepared at 25 ng/ml and diluted 1:1 down to
0.39 ng/ml for a standard curve (speciﬁcity was demonstrated by
heating both preparations for 10 minutes at 90

C and demon-
strating that this eliminated all activity).2.3.5. Catalase analysis
Following the method of Abei,32 the reaction was initiated by
adding 3 ml of of a buffer/H2O2 solution (60 ml of 30% in 50 mM
phosphate buffer, pH 7.8) in the presence of 50 ml of tissue extract.
The degradation of H2O2 was monitored at 240 nm for 6 minutes,
and an extinction coefﬁcient of 43.6 M1 cm1 was used to calcu-
late units of activity. The enzyme activity was expressed in units per
milligram protein (1 UNIT ¼ 1 mol of H2O2 degraded for 1 minute).
For comparative purposes, the slope of enzyme reaction was
utilized to demonstrate ChAT activity in units of mOD/minute/mg
protein.3. Results
Table 1 presents the values for the control groups for citrate
synthase, ChAT and MDA. For these parameters, the treatments had
no signiﬁcant effect on the control values and these groups were
combined. Citrate synthase activity andMDA content of themucosa
were signiﬁcantly higher than the values of the muscle.
Table 2 presents the numerical means  SEM and signiﬁcance
details for all data shown in ﬁgures.
Fig. 1 presents the effect of the three treatments on citrate
synthase activity as percent of control values. Partial outlet
obstruction (PBOO) resulted in a 60% decrease in citrate synthase
activity. Solifenacin had no effect on citrate synthase activity of the
bladder smooth muscle. However, pretreatment with both the
antioxidants, or the combination of solifenacin þ antioxidants
protected the citrate synthase activity such that it remained at
control values. No treatment had any signiﬁcant effect on the
reduced citrate synthase activity of the mucosa (Fig. 1).
ChAT of the bladder smooth muscle is presented in Fig. 2 as
percentage of control. Similar to citrate synthase, PBOO resulted in
a 60% decrease in ChAT activity, while solifenacin had no effect on
the reduced ChAT activity. Both the antioxidant and combination
therapy resulted in protecting ChATactivity such that it remained at
control values. As ChAT is involved in cholinergic neurotransmis-
sion to the bladder smooth muscle, only the muscle was analyzed.
The MDA content of the muscle and mucosa is presented in
Fig. 3. Obstruction resulted in a signiﬁcant increase in lipid perox-
idation (MDA content) of both the muscle and mucosa. For both
tissues, all treatments resulted in signiﬁcantly lower MDA content
when compared with no treatment.
The SOD of the muscle and mucosa is presented in Fig. 4. For
both tissues, obstruction resulted in decreased SOD activity
(increased IC25). Only the antioxidant pretreatment increased the
activity of the obstructed tissue to control values for both muscle
and mucosa. Catalase activity is presented in Fig. 5. In the mucosa,
obstruction caused reduced catalase activity in the no treatment,
antioxidant, and combined solifenacin þ antioxidant groups. The
control and obstructed antioxidant and combination groups had
signiﬁcantly higher catalase activity compared with the no treat-
ment control and obstructed groups. Interestingly, in the bladder
Table 2
Numerical values of data shown in ﬁgures.
Muscle Mucosa
No treat Sol CoQ þ LA Sol þ CoQ þ LA No treat Sol CoQ þ LA Sol þ CoQ þ LA
Citrate synthasea 37.2  6.8* 26.6  5.0* 114  8.0 x 116  13.0 x 55.7  7.6* 41.6  3.7* 66.0  9.0* 58.0  2.0*
ChATa 44.0  10* 42.0  18* 93.0  11 x 94.0  8.0 x
MDAa 318  90* 203  60 * x 152  24.6 x 138  53.1 x 227  59* x 112  50 x 140  15.0 x 105  25x
SODbdcontrol 1.8  0.7 2.0  0.16 2.0  0.7 2.4  0.04 1.2  0.05 1.0  0.04 1.0  0.06 1.2  0.03
SODbdobstructed 2.8  0.14* 3.0  0.1* 2.4  0.08 3.0  0.1* 1.5  0.06* 1.5  0.1* 1.2  0.06 1.6  0.3*
Catalasecdcontrol 0.63  0.03 0.56  0.03 0.42  0.01x 0.61  0.01 0.55  0.01 0.59  0.01 0.78  0.03 x 0.98  0.03 x
Catalasecdobstructed 0.77  0.06* 0.67  0.02* 0.53  0.02* x 0.67  0.01 0.32  0.01* 0.55  0.05 x 0.6  0.01* x 0.8  0.15* x
*Signiﬁcantly different from control; x ¼ signiﬁcantly different from no treatment; p < 0.05.
ChAT ¼ choline acetyltransferase; MDA ¼ malondialdehyde; No Treat ¼ no treatment; Sol ¼ solifenacin; SOD ¼ superoxide dismutase.
a Data presented as percentage of control values.
b Data presented as the IC - 25 (concentration that inhibits 25% of the activity of SOD).
c Data presented as mOD/minute/mg protein.
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the obstructed bladders (comparedwith control bladders) in the no
treatment, solifenacin, and antioxidant groups. The catalase activity
of the antioxidant control and obstructed groups were signiﬁcantly
lower than the activity of the respective no treatment groups.
3.1. Statistics
Analysis of variance was used to analyze the data, followed
by the Tukey test for individual differences among the groups.
A p < 0.05 was required for statistical signiﬁcance.
4. Discussion
Anti-muscarinic agents have proven to be clinically effective in
the treatment of overactive bladders in both men and women.33e35
These drugs relax the bladder by muscarinic cholinergic inhibition
whichmakes them useful for the treatment of the unstable bladder.
As both bladder overactivity andmicturition are primarily based on
the neuronal release of Ach and muscarinic receptor stimulation, it
is important to directly compare the effect of antimuscarinic agents
on these two cholinergic systems in a controlled, quantitative
manner, in which a true sensitivity can be determined for each
system. Moreover, it would be beneﬁcial to ﬁnd treatment modal-
ities that address overactivity without affecting bladder contractileMuscle Mucosa
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Fig. 1. Citrate synthase activity of the smooth muscle and mucosal compartments of
the rabbit bladder presented as percent of control activity. “Control activity” is the
enzyme activity of rabbits that were not subjected to either partial outlet obstruction
(PBOO) or in situ overactive bladder (OAB). The control values can be found in Table 1.
The “no treatment” group is the group of rabbits that did not receive any solefenacin or
antioxidants, but were subjected to PBOO and in vitro OAB. Each bar is the mean  SEM
of six individual rabbits. * ¼ signiﬁcantly different from control; x ¼ signiﬁcantly
different from no treatment; p < 0.05.force. This might be accomplished through the use of antioxidants,
as mentioned in the Introduction. For the current studies, we have
chosen to use the combination of coenzyme Q10 and alpha lipoic
acid because, as mentioned earlier, this combination of antioxi-
dants has been shown to be effective in the treatment of partial
outlet obstruction and in vivo ischemia/reperfusion.19,20,36
In part one of these studies, we evaluated these treatments on
bladder compliance, OAB amplitude and frequency, and in vitro
contractile responses to ﬁeld stimulation, carbachol, and KCl. In
general, all treatments improved compliance, reduced OAB, and
improved the contractile responses. However, the combination
therapy of solifenacin þ antioxidants was more effective than
either therapy alone.
Previous studies demonstrated that partial outlet obstruction and
OAB both result in the release of free radicals and oxidative damage,
especially to mitochondria, and to synaptic membranes and nerve
terminals.37e40 In the current studies, pretreatment with both the
antioxidants alone and the combination of solifenacin þ
antioxidants protected mitochondrial activity (citrate synthase
activity) and cholinergic synaptic function (ChAT activity) in the
bladder smooth muscle. Recent studies have clearly demonstrated
that there is non-neuronal Ach localized in the urothelium.41,42 The
release of Ach and other bioactive substances from the urothelium
may play a role in the etiology of OAB,42 and may be the reason
why antimuscarinic agents are not effective against OAB in allCh
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in situ overactive bladder (OAB). The control values can be found in Table 1. The “no
treatment” group is the group of rabbits that did not receive any solefenacin or anti-
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six individual rabbits. * ¼ signiﬁcantly different from control; x ¼ signiﬁcantly different
from no treatment; p < 0.05.
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T. Topol et al. / Urological Science 22 (2011) 141e146 145patients.43,44 Because of the rather extensive non-neuronal cholin-
ergic system in the urothelium, we only measured ChAT activity in
the muscle.
There was no protection observed for the mucosa in regard to
citrate synthase activity. This may be owing to the observed
mucosal structural damage caused by partial outlet obstruction.45,46
The MDA studies show that all three treatments protect lipidSu
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p < 0.05.
rabbit bladder. Each bar is the mean  SEM of six individual rabbits. * ¼ signiﬁcantly
different from control; x ¼ signiﬁcantly different from no treatment; p < 0.05.membrane components of both the muscle and mucosa from per-
oxidation. In general, the increased citrate synthase activity and
increased ChAT activity in association with reduced MDA levels in
the bladder smooth muscle are entirely consistent with the func-
tional improvements in bladder contractile responses and compli-
ance observed for the antioxidant and combination therapy groups.
Similar to the conclusions from part 1, it is clear that all three
forms of treatment were effective in improving the obstructed
bladder’s biochemical function. Taking all the studies into account,
the combination of solifenacin and antioxidants was more effective
in improving more parameters than either of the other two ther-
apies alone, thus supporting our original hypothesis.
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